Latest Conference Articles

September 8th 2017, 8:57pm

ESMO Congress

Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.

September 8th 2017, 3:48pm

ESMO Congress

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

July 6th 2017, 9:26pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Bastian Schilling, MD, University of Wuerzburg, discusses different types of ocular melanoma and the importance of distinguishing this subtype.

July 6th 2017, 9:23pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

July 6th 2017, 12:05am

European Post-Chicago Melanoma / Skin Cancer Meeting

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

July 5th 2017, 11:33pm

ESMO Gastrointestinal Cancers Congress

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

July 5th 2017, 11:29pm

ESMO Gastrointestinal Cancers Congress

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses napabucasin with FOLFIRI and bevacizumab (Avastin) in colorectal cancer.

July 2nd 2017, 12:38am

ESMO Gastrointestinal Cancers Congress

In a central evaluation for surgical treatment options in the FIRE-3 study results, investigators set out to determine the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.

July 1st 2017, 9:13pm

ESMO Gastrointestinal Cancers Congress

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses immunotherapy in gastrointestinal cancers.

July 1st 2017, 9:11pm

ESMO Gastrointestinal Cancers Congress

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the results of the CHARTA study in colorectal cancer.

July 1st 2017, 8:40pm

ESMO Gastrointestinal Cancers Congress

The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.

July 1st 2017, 8:02pm

ESMO Gastrointestinal Cancers Congress

CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.

July 1st 2017, 3:58am

European Post-Chicago Melanoma / Skin Cancer Meeting

Immune checkpoint inhibitors against PD-1 and PD-L1 are showing promise across clinical trials for patients with Merkel cell carcinoma.

July 1st 2017, 12:39am

ESMO Gastrointestinal Cancers Congress

Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.

June 30th 2017, 11:29pm

ESMO Gastrointestinal Cancers Congress

Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.

June 30th 2017, 11:23pm

ESMO Gastrointestinal Cancers Congress

Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.

June 30th 2017, 9:39pm

ESMO Gastrointestinal Cancers Congress

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

June 30th 2017, 9:34pm

ESMO Gastrointestinal Cancers Congress

Aparna R. Parikh, MD, medical oncologist, Massachusetts General Hospital, discusses liquid biopsies in gastrointestinal cancers.

June 30th 2017, 9:14pm

European Post-Chicago Melanoma / Skin Cancer Meeting

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.

June 30th 2017, 8:18pm

State of the Science Summit on Melanoma and Immuno-Oncology

Doug Kondziolka, MD, professor and vice chair of Clinical Research, NYU Langone Medical Center, discusses therapeutic approaches for patients with melanoma who have brain metastases.